TP53 and neoplasm: Our comprehensive genomic profiling reveals a convergent mutational landscape in TP53/RB1 co‐altered tumors, characterized by frequent alterations in chromatin remodeling and PI3K signaling pathways, suggesting TP53/RB1 loss drives tumor progression through broader oncogenic programs beyond core cell cycle dysregulation [24].